|Day Low/High||1.23 / 1.45|
|52 Wk Low/High||0.99 / 6.60|
Top Line Results Expected in 3Q 2017
Phase 2 MDD clinical trial results expected in 3Q17, Extended runway of cash into 3Q18
Investigating New Patient Cohort with Cervical Injury
TheStreet's biotech columnist offers his own report card on biotech stocks.
NSI-189 Shows Reversal of Radiation-induced Cognitive Deficits
NSI-189 Shows Prevention and Reversal of Diabetic Neuropathies in Mice
Dr. Karl Johe Resigns from Board of Directors; Company Announces Creation of Scientific Policy Committee with Dr. Johe as Chairman
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.